Non Small Cell Lung Cancer - atezolizumab - STK11 mutation + TMB-H + PD-L1 overexpression

Association details:

Biomarker:	STK11 mutation + TMB-H + PD-L1 overexpression
Cancer:	Non Small Cell Lung Cancer
Drug:	Tecentriq (atezolizumab) (PD-L1 inhibitor)
Direction:	Sensitive

Evidence:

Evidence Level:

Sensitive: C3 – Early Trials

Source:

Oncoimmunology

Title:

Atezolizumab prolongs overall survival over docetaxel in advanced non-small-cell lung cancer patients harboring STK11 or KEAP1 mutation

Published date:

01/15/2021

Excerpt:

In SKmut patients with aNSCLC, atezolizumab was associated with significantly longer overall survival in comparison to docetaxel. Having FAT3 mutation or high TMB and PD-L1 expression potentially predict favorable response in SKmut patients receiving atezolizumab.

DOI:

10.1080/2162402X.2020.1865670